On February 24, 2022, Russia launched a wide-ranging attack on Ukraine. In light of the continuously evolving and worsening conditions in the region, Karuna Therapeutics, Inc. is withdrawing its prior guidance for the timing of topline data for its ongoing Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia. At this time, the escalating conflict in Ukraine has created uncertainty around the Company's ability to project the timing of topline data from this trial.

The Company is actively monitoring the evolving geopolitical situation between Ukraine and Russia and the impact on clinical trial sites and operations. The safety of patients and clinical trial partners is the Company's priority. The Company continues to enroll and treat patients in the EMERGENT clinical program at its sites in the U.S., and will provide updates on its sites and operations in Ukraine, as appropriate.

The Company expects to provide updated guidance on the Phase 3 EMERGENT-3 trial once it is able to better understand the impact of recent developments in Ukraine on its ongoing trial.